地西他滨联合微移植与预激方案作为老年急性髓系白血病巩固治疗的疗效比较
回顾性分析37例≥60岁首次完全缓解的急性髓系白血病患者,19例接受地西他滨联合微移植巩固,18例接受地西他滨联合预激方案化疗。两组3~4级非血液学毒性无显著差异,微移植组2年无白血病生存率50.7%优于化疗组24.3%(P=0.047),作者认为该方案可能安全有效。
要点
- 微移植组与化疗组CTC 3~4级非血液学不良反应发生率分别为36.8%和27.8%,差异无统计学意义。
- 微移植组2年无白血病生存率50.7%优于化疗组24.3%(P=0.047)。
- 微移植组未发生移植物抗宿主病,作者认为该巩固方案可能安全有效。
核心结论
- 对于老年急性髓系白血病患者,地西他滨联合微移植作为巩固方案可能是一种安全且有前景的选择。
研究设计与样本
- 回顾性分析2012年11月至2015年9月诊治的37例≥60岁首次完全缓解的急性髓系白血病患者病例资料。
主要发现
- 两组起病时年龄、WBC水平、疾病状态差异均无统计学意义(P值均>0.05)。
- 微移植组与化疗组CTC 3~4级非血液学不良反应发生率分别为36.8%(7/19)和27.8%(5/18),差异无统计学意义(χ²=0.347,P=0.728)。
- 微移植组与化疗组中性粒细胞恢复中位时间分别为12和13天(z=1.599,P=0.110),血小板恢复中位时间分别为14和12天(z=-1.314,P=0.189)。
- 微移植组患者均未发生移植物抗宿主病。
- 微移植组与化疗组2年无白血病生存率分别为50.7%和24.3%(P=0.047),2年总生存率分别为54.9%和30.0%(P=0.071)。
临床怎么用
- 作者认为地西他滨联合微移植可能是一种安全有效的巩固方案,可用于老年急性髓系白血病患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To probe the feasibility of decitabine (DAC) combined with micro-transplantation as consolidation treatment for older patients with acute myeloid leukemia (AML). Methods: Between November 2012 and September 2015, 37 consecutive patients with AML ≥60 years of age were analyzed. Of them, 19 patients received consolidation therapy with DAC followed by micro-transplantation (microtransplant group). Another 18 ones (chemo group) were treated with DAC plus priming regimen as consolidation chemotherapy in the same period. Results: There were no significant differences in terms of age, WBC count, and disease status of onset between the microtransplant and chemo groups (P>0.05). The two regimens were well tolerated. There was no difference of CTC grade 3-4 nonhematologic toxicities between the microtransplant and chemo groups (36.8% vs 27.8%, χ(2)=0.347, P=0.728). The median recovery durations for neutrophil and platelet in the microtransplant group were similar to those in the chemo group (12 vs 13 days, z=1.599, P=0.110; 14 vs 12 days, z=-1.314, P=0.189, respectively). No graft-versus-host disease was observed in the microtransplant group. The 2-year leukemia-free survival and overall survival were better in microtransplant group (50.7% and 54.9%, respectively) than in chemo group (24.3% and 30.0%, respectively) (P=0.047 and P=0.071, respectively). Conclusion: DAC combined with micro-transplantation as a consolidation regimen may be a safe and promising option for older patients with AML. 目的: 探索老年急性髓系白血病(AML)第1次完全缓解(CR(1))后采用地西他滨联合微移植巩固治疗的疗效与安全性。 方法: 回顾性分析2012年11月至2015年9月诊治的37例CR(1)老年(≥60岁)AML患者病例资料,比较分析地西他滨联合微移植(微移植组,19例)与地西他滨联合预激方案巩固治疗(化疗组,18例)的疗效和不良反应。 结果: 两组患者起病时的年龄、WBC水平、疾病状态差异均无统计学意义(P值均>0.05)。两种巩固治疗方案的耐受性均良好,微移植组与化疗组的CTC 3~4级非血液学不良反应发生率差异无统计学意义[36.8%(7/19)对27.8%(5/18),χ(2)=0.347,P=0.728]。微移植组与化疗组中性粒细胞恢复的中位时间分别为12和13 d(z=1.599,P=0.110),血小板恢复的中位时间分别为14和12 d(z=-1.314,P=0.189)。微移植组患者均未发生移植物抗宿主病。微移植组与化疗组的2年无白血病生存率分别为50.7%和24.3%(P=0.047),2年总生存率分别为54.9%和30.0%(P=0.071)。 结论: 对于老年AML患者,地西他滨联合微移植可能是一种安全有效的巩固方案。.
引用
- Li WY, Feng YF, Ma X, et al. [Comparison of the efficacy of decitabine combined with micro-transplantation or priming regimen as consolidation treatment for older patients with acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29779327. doi:10.3760/cma.j.issn.0253-2727.2018.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。